GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated ...

The market for GSK plc's ( LON:GSK) shares didn't move much after it posted weak earnings recently. We did some digging, and ...

The US group's division has reported a pre-tax profit of $39.5m (£30.6m) for the 12 months to 31 January, 2024, according to ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

The UK’s benchmark FTSE 100 index fell on Wednesday, dragged by healthcare shares after GSK warned of lower annual vaccine ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales. The company ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

UK pharma major GSK looked set to close Wednesday’s trading around 3% lower. The London-based drugmaker earlier presented its ...

The collaboration agreement was signed by Dr. Ramadan Al Blooshi, Advisor to the Director General and Acting Director of the ...

The University of Cambridge and GSK (GlaxoSmithKline) have started a new five-year collaboration aiming to improve outcomes ...